Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9
REDWOOD CITY, Calif., Sept. 3, 2015 /PRNewswire/ -- Guardant Health®, the leader in liquid biopsies, announced today that five abstracts highlighting the performance and clinical utility of Guardant360® on lung cancer patients have been accepted for oral and poster presentations at the International Association for the Study of Lung Cancer's 16th World Conference on Lung Cancer. These abstracts were submitted by MD Anderson Cancer Center; the University of California, Davis; the University of Chicago; Sarah Cannon Research Institute; and Northwestern University. Guardant Health Chief Medical Officer Dr. Richard Lanman will also present "Guardant360: Clinical Impact of Biopsy-Free Sequencing in NSCLC" at the exhibit showcase.
Today's news continues Guardant Health's momentum in the marketplace: in 2015 more than 1,000 oncologists have ordered Guardant360 for multiple cancer types, and especially in lung as issues with tissue availability, tissue heterogeneity, biopsy cost and complications can be largely eliminated with Guardant360. Accordingly, SWOG recently selected Guardant360 for its 600-patient S1403 lung cancer study, the largest prospective clinical outcomes study using liquid biopsy for genomic tumor profiling. In this study, patients on a novel combination EGFR blockade will be monitored using Guardant360.
Leading oncologists specializing in lung cancer are currently using Guardant360 to identify emerging tumor genomic alterations and unlock potentially overlooked treatment options for their patients. The data presented at World Conference on Lung Cancer will highlight the clinical utility of Guardant360 for lung cancer, as well as detail performance in tracking clinical response.
The schedule of presentations
Podium presentations:
Date and Time: 4:45 p.m.-6:15 p.m. MST, Monday, Sept. 7
Session Name: Mini Oral 07: ChemoRT and Translational Science
Subject: Dynamic Changes in Cell-Free Circulating Tumor DNA to Track Tumor Response and Risk of Recurrence in Stage III Non-Small Cell Lung Cancer
Session Type: Oral Presentation
Location: 201 + 203
Presenter: Steven Lin, MD, The University of Texas MD Anderson Cancer Center
Date and Time: 4:45 p.m.-6:15 p.m. MST, Wednesday, Sept. 9
Session Name: Oral Session 38: Liquid Biopsies
Subject: Identification of Actionable Tumor Alterations in Circulating Cell-Free Tumor DNA (cf DNA) Using Digital Sequencing from NSCLC Patients
Session Type: Oral Presentation
Location: Mile High Ballroom 2a-3b
Presenter: Philip Mack, PhD, UC Davis
Date and Time: 4:45 p.m.-6:15 p.m. MST, Wednesday, Sept. 9
Session Name: Oral Session 38: Liquid Biopsies
Subject: Biopsy-Free Circulating Tumor DNA Assay Identifies Actionable Mutations in Lung Cancer
Session Type: Oral Presentation
Location: Mile High Ballroom 2a-3b
Presenter: Victoria Villaflor, MD, University of Chicago
Poster presentations:
Date and Time: 9:30 a.m.-5:00 p.m. MST, Wednesday, Sept. 9
Subject: Comparing next-generation sequencing (NGS) platforms in patients with thoracic tumors: tumor tissue vs. circulating cell-free DNA from blood
Poster #: 1732
Location: Exhibit Hall (Hall B + C)
Authors: Johnson, M.L. et al.
Date and Time: 9:30 a.m.-5:00 p.m. MST, Wednesday, Sept. 9
Subject: EML-ALK fusion in a non-small cell lung cancer patient detected by high sensitivity circulating tumor DNA assay empowers targeted therapy decisions
Location: Exhibit Hall (Hall B + C)
Poster #: 2259
Authors: Nisha Mohindra, Becky Nagy, Bahram Kermani, Stefanie Mortimer, Richard B. Lanman, Helmy Eltoukhy, Amir A. Talasaz, Jyoti Patel
Exhibit Showcase
Date and Time: 12:30-1:00 p.m. MST, Tuesday, Sept. 8
Subject: Guardant360: Clinical Impact of Biopsy-Free Sequencing in NSCLC
Location: Showcase Theater
Presenter: Rick Lanman, MD, Guardant Health
Guardant Health is also an exhibitor at the IASLC's 16th World Conference on Lung Cancer. Company representatives will be available to provide additional information on Guardant Health and its product, Guardant360, at the company's booth, #3222. To learn more, visit www.guardanthealth.com.
With only two vials of blood, Guardant360 digitally sequences more than 10 billion genomic data points to identify tumor genomic alterations at greater than 99.9999 percent specificity. Guardant identifies actionable genomic alterations and associated treatments in about half the turnaround-time – and with none of the risk – of tissue biopsies. The Guardant360 platform gives oncologists and patients a simpler, faster, and more accurate perspective of their treatment options, resulting in targeted therapies for genomic alterations.
About Guardant Health
Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics, and cancer diagnostics. The company has raised $100 million in funding from leading venture capital firms and its first product, Guardant360, came to market in 2014. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology. The World Economic Forum named Guardant Health a 2015 Technology Pioneer.
Media Contact:
Mark de la Vina
Consort Partners for Guardant Health
Email: [email protected]
Phone: 415-282-4795
SOURCE Guardant Health
Share this article